PMID- 31258666
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 18
IP  - 1
DP  - 2019 Jul
TI  - Early short-term ivabradine treatment in new-onset acute systolic heart failure 
      and sinus tachycardia patients with inflammatory rheumatic disease.
PG  - 305-311
LID - 10.3892/etm.2019.7531 [doi]
AB  - Acute heart failure (AHF) is a common complication of inflammatory rheumatic 
      disease (IRD) and usually coexists with tachycardia. Ivabradine, a direct sinus 
      node inhibitor, which was proven to have favorable effects in patients with 
      chronic HF (CHF), has not been sufficiently evaluated in AHF patients regarding 
      its efficacy and safety. The present study sought to explore the effectiveness of 
      early short-term ivabradine treatment in new-onset AHF and concurrent sinus 
      tachycardia in patients with IRD. A total of 12 consecutive patients with IRD, 
      who had new-onset AHF and concurrent sinus tachycardia, were prescribed 
      ivabradine and were retrospectively recruited. Standard medication therapy for 
      AHF was also administered. The heart rate (HR), left ventricular ejection 
      fraction (LVEF), biomarkers of HF and New York Heart Association (NYHA) 
      classification score were compared prior to and after ivabradine treatment. After 
      48 h of treatment with ivabradine, the mean resting HR decreased from 118.0+/-13.8 
      to 83.3+/-7.3 bpm (P<0.001). Transthoracic echocardiography indicated a significant 
      improvement in the LVEF on an average of 2 weeks after ivabradine prescription 
      when compared with the baseline evaluation (51.2+/-8.4 vs. 38.0+/-9.0%; P<0.001). In 
      addition, ivabradine treatment resulted in significantly decreased N-terminal 
      proB-type natriuretic peptide (4,900+/-3,672 vs. 16,806+/-16,130 pg/ml; P=0.045) and 
      improvement of the NYHA classification score (2.3+/-0.6 vs. 3.5+/-0.5; P<0.001) at 2 
      weeks when compared with the baseline. Overall, the results of the present study 
      suggested that early use of ivabradine is safe in IRD patients with new-onset AHF 
      and enhances the sinus rate reduction, which may improve heart function.
FAU - Wu, Wei
AU  - Wu W
AD  - Department of Cardiology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Science, Beijing 100730, P.R. 
      China.
FAU - Zhang, Lixi
AU  - Zhang L
AD  - Department of Cardiology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Science, Beijing 100730, P.R. 
      China.
FAU - Zhao, Jiuliang
AU  - Zhao J
AD  - Department of Rheumatology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Science, Beijing 100730, P.R. 
      China.
FAU - Guo, Yuchao
AU  - Guo Y
AD  - Department of Cardiology, The Second Affiliated Hospital of Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang 310009, P.R. China.
FAU - Liu, Jinjing
AU  - Liu J
AD  - Department of Rheumatology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Science, Beijing 100730, P.R. 
      China.
FAU - Shi, Di
AU  - Shi D
AD  - Department of Emergency, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Science, Beijing, P.R. China.
FAU - Yang, Jing
AU  - Yang J
AD  - Department of Emergency, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Science, Beijing, P.R. China.
FAU - Liu, Yingxian
AU  - Liu Y
AD  - Department of Cardiology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Science, Beijing 100730, P.R. 
      China.
FAU - Lai, Jinzhi
AU  - Lai J
AD  - Department of Cardiology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Science, Beijing 100730, P.R. 
      China.
FAU - Shen, Zhujun
AU  - Shen Z
AD  - Department of Cardiology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Science, Beijing 100730, P.R. 
      China.
LA  - eng
PT  - Journal Article
DEP - 20190425
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC6566021
OTO - NOTNLM
OT  - acute heart failure
OT  - heart rate
OT  - inflammatory rheumatic disease
OT  - ivabradine
OT  - tachycardiomyopathy
EDAT- 2019/07/02 06:00
MHDA- 2019/07/02 06:01
PMCR- 2019/04/25
CRDT- 2019/07/02 06:00
PHST- 2018/09/01 00:00 [received]
PHST- 2019/04/05 00:00 [accepted]
PHST- 2019/07/02 06:00 [entrez]
PHST- 2019/07/02 06:00 [pubmed]
PHST- 2019/07/02 06:01 [medline]
PHST- 2019/04/25 00:00 [pmc-release]
AID - ETM-0-0-7531 [pii]
AID - 10.3892/etm.2019.7531 [doi]
PST - ppublish
SO  - Exp Ther Med. 2019 Jul;18(1):305-311. doi: 10.3892/etm.2019.7531. Epub 2019 Apr 
      25.